Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiosyentTSXV:RX -0.07%98 EV-to-FCF is 13.18 as of Jul. 14, 2026, which is 20% below its 10-year median of 16.54. GuruFocus rates TSXV:RX with a GF Score™ of 98/100 and a GF Value™ of C$16.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, Biosyent ranks better than 68.86% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biosyent's Enterprise Value is C$159.68 Mil.
Biosyent's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$12.12 Mil. Therefore, Biosyent's EV-to-FCF for today is 13.18.
The historical rank and industry rank for Biosyent's EV-to-FCF or its related term are showing as below:
TSXV:RX'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.85 Med: 16.54 Max: 64.65
Current: 13.18
During the past 13 years, the highest EV-to-FCF of Biosyent was 64.65. The lowest was 6.85. And the median was 16.54.
TSXV:RX's EV-to-FCF is ranked better than 68.86% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs TSXV:RX: 13.18
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biosyent's share price for today is C$14.59.
Biosyent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.788.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biosyent EV-to-FCF Related Terms
Biosyent EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Biosyent's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosyent EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biosyent's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biosyent's EV-to-FCF falls into.
Biosyent's current Enterprise Value is C$159.68 Mil.
Biosyent's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$12.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosyent (TSXV:RX) has a EV-to-FCF of 13.18 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biosyent and its competitors. This is 20% below median its historical median of 16.54. Over the past decade, Biosyent's EV-to-FCF has ranged from 6.85 to 64.65. According to the industry distribution chart, Biosyent ranks #175 out of 562 companies in the Drug Manufacturers industry, placing it in the top 31.1%.
Is Biosyent's EV-to-FCF too high?
Biosyent's current EV-to-FCF of 13.18 is 20% below median its 10-year median of 16.54. Over the past 10 years, this metric has ranged from a low of 6.85 to a high of 64.65. The Drug Manufacturers industry median EV-to-FCF is 21.06. Biosyent's value of 13.18 is 37.4% below this industry median. Based on the distribution chart, Biosyent ranks #175 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biosyent has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biosyent's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biosyent ranks #175 out of 562 companies for EV-to-FCF. This puts Biosyent in the upper half of its industry. The industry median EV-to-FCF is 21.06. Biosyent's value of 13.18 is 37.4% below this benchmark. Historically, Biosyent's own EV-to-FCF has ranged from 6.85 to 64.65 over the past decade. While the company's 10-year median is 16.54 vs. the industry median of 21.06, Biosyent has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosyent's current EV-to-FCF of 13.18 is 37.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biosyent and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosyent's current EV-to-FCF is 13.18, which is 20% below median its own 10-year median of 16.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosyent stock overvalued right now?
Based on GuruFocus' analysis, Biosyent (TSXV:RX) is currently considered Modestly Undervalued. The stock's GF Value™ is C$16.56, compared to a current price of C$14.59 — trading 11.9% below its estimated fair value. The current EV-to-FCF is 13.18, which is 20% below median its 10-year median of 16.54 and 37.4% below the Drug Manufacturers industry median of 21.06. Biosyent's overall GF Score™ is 98/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biosyent (TSXV:RX), the current EV-to-FCF is 13.18 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosyent (TSXV:RX) Overvalued in 2026?
Based on GuruFocus' analysis, Biosyent stock appears to be undervalued.
The current stock price of C$14.59 is trading 11.9% below its estimated GF Value™ of C$16.56.
GuruFocus considers Biosyent to be Modestly Undervalued.
Key valuation signals for TSXV:RX:
EV-to-FCF: 13.18 (20% below median its 10-year median of 16.54)
GF Value™: C$16.56 vs. price of C$14.59 (11.9% below fair value)
Industry Position: 37.4% below the Drug Manufacturers median (#175 of 562)
No single metric tells the full story. See the TSXV:RX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.
98GF Score
Get the complete analysis for TSXV:RX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:RX has been successfully added to your 
